モルフィック・ホールディング【MORF】の掲示板

強いなぁ🙌

😒🚬🈁
75$🤭
サンキュー😉👍🎶

😒🚬🈁

Over the last twelve months, Morphic Holding's revenue grew by 88%. That's well above most other pre-profit companies. And the share price has responded, gaining 126% as we previously mentioned. It's great to see strong revenue growth, but the question is whether it can be sustained. Given the positive sentiment around the stock we're cautious, but there's no doubt its worth watching.

😒🚬🈁
バイオに
うってつけの地合いに✨

😒🈁🚬
71$🤭
来た来た🎵

😒🚬🈁
再度❗
🈁化ける気がする🤭

何故大きく騰がったのですか。教えてください。！！！！！！！！

こんな上がってたのかな👀深追いしないのが裏目に😂

すごいな。

😒🚬🈁
(^o^ゞ90$‼️

😒🚬🈁


GlobeNewswire



REGISTERSIGN IN

ENGLISHFRANÇAIS

CONTACT USGLOBAL DISTRIBUTIONNEWSWIRE SERVICESREGULATORY FILINGSMEDIA PARTNERS




Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020

  

March 01, 2021 06:55 ET | Source: Morphic Therapeutic

Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057
AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases
Expanded research and development collaboration with Janssen through third integrin program
Conference call today at 8:00 a.m. ET
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2020.
2020 and Recent Corporate Highlights

Filed first IND of an oral integrin drug candidate, MORF-057, generated by Morphic’s MInT Platform and initiated first clinical study of MORF-057 in healthy volunteers in Phase 1 clinical trial of oral IBD candidate, MORF-057, after acceptance of IND by Food and Drug Administration

Announced positive preliminary results from Phase 1 single ascending dose portion of MORF-057 Phase 1 clinical trial including:

MORF-057 well tolerated in all five dose cohorts ranging from 25 mg to 400 mg

MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 at the three highest dose levels

Phase 1 multiple ascending dose and food effect trials ongoing with full data anticipated to be presented mid-year 2021

Received $20 million payment upon AbbVie exercise of a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors, including the compounds MORF-720 and MORF-627

Expanded research and development collaboration with Janssen through a third integrin program

Presented promising preclinic

深追いしたくないんで半分利確🤑

やっぱりバイオは魅力あり😁

爆上げーーーー🙌

モーフィック・ホールディングについて話し合うスレッドです。
スレッドのテーマと無関係のコメント、もしくは他にふさわしいスレッドがあるコメントは削除されることがあります。

textreamのビジネス、株式、金融、投資、または証券に関するスレッドに参加する場合は、Yahoo! JAPAN利用規約を再読してください。

Yahoo! JAPANは情報の内容や正確さについて責任を負うことはできません。
その種の情報に基づいて行われた取引や投資決定に対しては、Yahoo! JAPANは何ら責任を負うものではありません。